Article
Rheumatology
Andrew R. Melville, Md Yuzaiful Md Yusof, John Fitton, Leticia Garcia-Montoya, Lynda Bailey, Shouvik Dass, Paul Emery, Maya H. Buch, Benazir Saleem
Summary: The study evaluated the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with rheumatoid arthritis. The results showed that non-medical switch to RTX-B was largely effective, with factors like comorbidities, previous biologic DMARDs, and RTX-O treatment history influencing switch decisions.
Article
Immunology
Anuja Singh, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Tanveer Naved, Saurabh Bhatia, Ahmed Al-Harrasi, Prasun Chakrabarti, Lotfi Aleya, Celia Vargas-De-La-Cruz, Simona Bungau
Summary: Rheumatoid arthritis is an autoimmune disease characterized by severe inflammation that damages tendons, cartilage, and bones. B cells play a significant role in the pathogenesis of RA, and targeting B cells has shown therapeutic efficacy in treating autoantibody-related conditions, including RA. The development of B-cell-targeted therapies has led to a better understanding of the diverse roles of B cells in autoimmune diseases and their potential as effective treatment targets.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Rheumatology
Caitlin Norris-Grey, Geraldine Cambridge, Samantha Moore, Venkat Reddy, Maria Leandro
Summary: This study retrospectively reviewed the long-term persistence of rituximab in RA patients and identified factors associated with treatment discontinuation. The study found that many RA patients achieve good disease control with repeated cycles of rituximab treatment, but the main reason for discontinuation is treatment inefficacy. Seronegative patients and those who have previously failed other biologic DMARDs are at higher risk of drug discontinuation.
Article
Medicine, General & Internal
James I. Robinson, Md Yuzaiful Md Yusof, Vinny Davies, Dawn Wild, Michael Morgan, John C. Taylor, Yasser El-Sherbiny, David L. Morris, Lu Liu, Andy C. Rawstron, Maya H. Buch, Darren Plant, Heather J. Cordell, John D. Isaacs, Ian N. Bruce, Paul Emery, Anne Barton, Timothy J. Vyse, Jennifer H. Barrett, Edward M. Vital, Ann W. Morgan, MATURA Consortia, MASTERPLANS Consortia
Summary: This study evaluated the impact of FCGR variants on clinical response and immune cell function in rituximab therapy. The study found that FCGR3A-158V variant and increased copy numbers were associated with better clinical response in rheumatoid arthritis patients. In systemic lupus erythematosus patients, FCGR3A-158V variant and FCGR2C-ORF copy numbers were associated with better clinical response. Furthermore, NK cell Fc gamma RIIIa expression and ADCC were associated with clinical response and B-cell depletion.
Review
Immunology
Masanori A. Murayama, Jun Shimizu, Chie Miyabe, Kazuo Yudo, Yoshishige Miyabe
Summary: Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation and bone destruction in multiple joints. Inflammatory cytokines, such as IL-6 and TNF-alpha, play crucial roles in RA development. Biological therapies targeting these cytokines have revolutionized RA treatment, but non-responsiveness is still a challenge. This review focuses on the pathogenic roles of chemokines and their receptors in RA and discusses their potential as therapeutic targets.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Rheumatology
Merel A. A. Opdam, J. H. de Leijer, Nathan den Broeder, Rogier M. Thurlings, Wilfred van der Weele, Michael T. Nurmohamed, Marc R. Kok, Lenny van Bon, David F. Ten Cate, Lise M. Verhoef, Alfons A. den Broeder
Summary: In this post hoc analysis of the REDO trial, it was found that potential mediators such as circulating B-cell counts, immunoglobulin levels, neutrophil counts, and drug use did not explain the observed dose-dependent infection risk. Additionally, a trend towards higher infection rates shortly after RTX infusion was identified.
Article
Rheumatology
Maria Prendecki, Candice Clarke, Helena Edwards, Stacey McIntyre, Paige Mortimer, Sarah Gleeson, Paul Martin, Tina Thomson, Paul Randell, Anand Shah, Aran Singanayagam, Liz Lightstone, Alison Cox, Peter Kelleher, Michelle Willicombe, Stephen P. McAdoo
Summary: SARS-CoV-2 vaccines are immunogenic in patients receiving immunosuppression, though the response is impaired compared to healthy individuals. B-cell depletion following rituximab impairs serological responses, but T-cell responses are preserved in this group. Repeat vaccine doses for serological non-responders could be considered to induce more robust immunological response.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Immunology
Mohamed M. NasrAllah, Mahmoud Elalfy, Mervat El Ansary, Yasser Elmeseery, Ihab Amer, Paolo Malvezzi, Lionel Rostaing
Summary: Obinutuzumab (OBZ) effectively reduced B-cell counts in kidney-transplant candidates and had no effect on CDC crossmatch results, unlike rituximab (RTX).
Article
Rheumatology
Gerasimos Evangelatos, George E. Fragoulis, Kalliopi Klavdianou, Melina Moschopoulou, Dimitrios Vassilopoulos, Alexios Iliopoulos
Summary: The study found that 43% of rheumatoid arthritis patients treated with RTX developed HGG. Patients who developed low IgG or low IgM had lower baseline levels than those who did not, and the development of low IgM was associated with better disease outcomes.
Article
Immunology
Gemma Vidal-Pedrola, Najib Naamane, James A. Cameron, Arthur G. Pratt, Andrew L. Mellor, John D. Isaacs, Dagmar Scheel-Toellner, Amy E. Anderson
Summary: Age-associated B cells (ABCs) are an immune cell subset linked to autoimmunity, infection, and aging. Studies have shown that ABCs in the peripheral blood of patients with early rheumatoid arthritis (eRA) exhibit distinct transcriptional characteristics compared to control groups, and they are found to be abundant in synovial fluid. These activated B cells express chemokine receptors and adhesion molecules that favor inflammation over lymphoid tissue, and they may play a role in autoimmune pathology due to their antigen presentation and pro-inflammatory phenotype.
Article
Immunology
Constantina A. Bounia, Stamatis-Nick C. Liossis
Summary: Treatment with rituximab (RTX) significantly reduces circulating Th17 cell percentages in patients with RA, while Tregs remain stable. Reduction of Th17 cells is particularly evident in responders to RTX treatment, ACPA+ and RF (-) patients with RA.
CLINICAL IMMUNOLOGY
(2021)
Article
Rheumatology
Yann Nguyen, Xavier Mariette, Jacques E. Gottenberg, Michele Iudici, Jacques Morel, Olivier Vittecoq, Arnaud Constantin, Rene-Marc Flipo, Thierry Schaeverbeke, Jean Sibilia, Philippe Ravaud, Raphael Porcher, Raphaele Seror
Summary: This study found that only a small percentage of rheumatoid arthritis patients in real-life settings met all eligibility criteria from drug-registration trials. Non-eligible patients had lower treatment responses and higher risks of serious adverse events. The efficacy and safety data from registration trials may not be applicable to real-world RA patients receiving RTX treatment.
Article
Rheumatology
Roba Ghossan, Omar Al Tabaa, Alice Combier, Alexia Steelandt, Marion Thomas, Olivier Fogel, Corinne Miceli-Richard, Anna Molto, Yannick Allanore, Jerome Avouac
Summary: Maintaining complete B cell (BC) depletion does not appear to be a therapeutic target to achieve in rheumatoid arthritis (RA) patients in long-term maintenance therapy with rituximab (RTX).
Article
Medicine, General & Internal
Michaela Koehm, Ann C. Foldenauer, Tanja Rossmanith, Rieke Alten, Martin Aringer, Marina Backhaus, Gerd R. Burmester, Eugen Feist, Herbert Kellner, Klaus Krueger, Ulf Mueller-Ladner, Andrea Rubbert-Roth, Hans-Peter Tony, Siegfried Wassenberg, Harald Burkhardt, Frank Behrens
Summary: In patients with rheumatoid arthritis, retreatment with rituximab at doses of 500 mg and 1000 mg showed comparable efficacy. However, among patients initially treated with placebo, the initial dose of rituximab at 500 mg was associated with lower treatment response rates.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Yan Yan, Wei Zhao, Wei Liu, Yan Li, Xu Wang, Jingna Xun, Chantsalmaa Davgadorj
Summary: CCL19 enhances Ag-responsive IFN-γ(+) CD8(+) T cells in patients with HBV infection and promotes rapid clearance of intrahepatic HBV in mice.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Dermatology
Renaud Felten, Dan Lipsker, Jean Sibilia, Francois Chasset, Laurent Arnaud
Summary: The term lupus has been used since the Middle Ages to refer to several diseases characterized by ulcerous lesions. In the 19th century, a distinction between different types of lupus emerged, and the systemic nature of the disease was recognized. Modern treatments such as glucocorticoids, hydroxychloroquine, and immunosuppressive agents emerged in the second half of the 20th century. In the 21st century, there has been a deeper understanding of the disease's pathogenesis and the development of biologic and targeted treatments.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Rheumatology
Nadege Cordel, Celine Derambure, Sophie Coutant, Xavier Mariette, Denis Jullien, Sebastien Debarbieux, Olivier Chosidow, Alain Meyer, Didier Bessis, Pascal Joly, Alexis Mathian, Herve Levesque, Jean-Christophe Sabourin, Isabelle Tournier, Olivier Boyer
Summary: This study deep sequenced the TRIM33 gene in tumours from patients with cancer-associated anti-TIF1 gamma autoantibody-positive DM, identifying potential somatic variants. The results support the hypothesis of a role of TRIM33 gene mutations in the pathophysiology of anti-TIF1 gamma autoantibody-positive DM, consistent with previous reports.
Article
Rheumatology
Renaud Felten, Maxime Dubois, Manuel F. Ugarte-Gil, Aurore Chaudier, Lou Kawka, Hugo Bergier, Charlotte Costecalde, Luc Pijnenburg, Jeremy Fort, Emmanuel Chatelus, Christelle Sordet, Rose-Marie Javier, Jacques-Eric Gottenberg, Jean Sibilia, Yurilis J. Fuentes-Silva, Laurent Arnaud
Summary: The study identified three distinct clusters of AIIRD patients with different attitudes towards SARS-CoV-2 vaccination: voluntary, hesitant, and suspicious. Differences in vaccination willingness among these clusters were mainly related to specific concerns about vaccination, rather than fear of COVID-19 infection or frailty. This research may help improve communication strategies to increase COVID-19 vaccine coverage among AIIRD patients.
Article
Rheumatology
Bernard Combe, Nathalie Rincheval, Francis Berenbaum, Patrick Boumier, Alain Cantagrel, Philippe Dieude, Maxime Dougados, Bruno Fautrel, Rene-Marc Flipo, Philippe Goupille, Xavier Mariette, Alain Saraux, Thierry Schaeverbeke, Jean Sibilia, Olivier Vittecoq, Jean-Pierre Daures
Summary: The 10-year outcome of patients with early rheumatoid arthritis (RA) from the ESPOIR cohort showed favorable results, with a significant proportion achieving remission and good control of symptoms. However, some patients developed new comorbidities over the follow-up period, and positivity for anti-citrullinated peptides antibodies (ACPA) was confirmed as a strong predictor of long-term outcome.
Article
Rheumatology
Dan Levy, Benoit Nespola, Margherita Giannini, Renaud Felten, Francois Severac, Coralie Varoquier, Marina Rinagel, Anne-Sophie Korganow, Thierry Martin, Vincent Poindron, Francois Maurier, Haitham Chereih, Bastien Bouldoires, Baptiste Hervier, Cedric Lenormand, Emmanuel Chatelus, Bernard Geny, Jean Sibilia, Laurent Arnaud, Jacques-Eric Gottenberg, Alain Meyer
Summary: In myositis patients, Sjogren's syndrome is associated with inclusion body myositis and anti-cN1A antibodies, independently of the IBM diagnosis. As a consequence, anti-cN1A has limited specificity for IBM in myositis patients with Sjogren's syndrome.
Letter
Rheumatology
Renaud Felten, Pierre-Marie Duret, Elodie Bauer, Nathanael Sedmak, Julien H. Djossou, Massiva Bensalem, Marc Ardizzone, Marion Geoffroy, Angelique Fan, Marion Couderc, Jean Hugues Salmon, Laurent Messer, Rose-Marie Javier, Alain Meyer, Emmanuel Chatelus, Christelle Sordet, Luc Pijnenburg, Jeremy Fort, Marina Rinagel, Julia Walther, Cassandre Fabre, Laurent Arnaud, Jean Sibilia, Nicolas Meyer, Francis Berenbaum, Isabelle Chary-Valckenaere, Martin Soubrier, Jeremie Sellam, Jacques-Eric Gottenberg
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
L. Widawski, T. Fabacher, L. Spielmann, J. E. Gottenberg, J. Sibilia, P. M. Duret, L. Messer, R. Felten
Summary: This study aimed to investigate the effects of hyperuricemia on the clinical presentation, severity, and associated comorbidities of psoriatic arthritis (PsA). The results showed that patients with hyperuricemic PsA had a higher prevalence of male gender, higher body mass index, and more comorbidities compared to patients with normal uric acid levels. Hyperuricemic PsA was associated with older age at onset, more polyarticular and destructive joint involvement. Additionally, hyperuricemic PsA patients had a poorer response to treatment and more peripheral joint damage than normo-uricemic patients.
CLINICAL RHEUMATOLOGY
(2022)
Article
Cell Biology
Raphael Carapito, Richard Li, Julie Helms, Christine Carapito, Sharvari Gujja, Veronique Rolli, Raony Guimaraes, Jose Malagon-Lopez, Perrine Spinnhirny, Alexandre Lederle, Razieh Mohseninia, Aurelie Hirschler, Leslie Muller, Paul Bastard, Adrian Gervais, Qian Zhang, Francois Danion, Yvon Ruch, Maleka Schenck, Olivier Collange, Thien-Nga Chamaraux-Tran, Anne Molitor, Angelique Pichot, Alice Bernard, Ouria Tahar, Sabrina Bibi-Triki, Haiguo Wu, Nicodeme Paul, Sylvain Mayeur, Annabel Larnicol, Geraldine Laumond, Julia Frappier, Sylvie Schmidt, Antoine Hanauer, Cecile Macquin, Tristan Stemmelen, Michael Simons, Xavier Mariette, Olivier Hermine, Samira Fafi-Kremer, Bernard Goichot, Bernard Drenou, Khaldoun Kuteifan, Julien Pottecher, Paul-Michel Mertes, Shweta Kailasan, M. Javad Aman, Elisa Pin, Peter Nilsson, Anne Thomas, Alain Viari, Damien Sanlaville, Francis Schneider, Jean Sibilia, Pierre-Louis Tharaux, Jean-Laurent Casanova, Yves Hansmann, Daniel Lidar, Mirjana Radosavljevic, Jeffrey R. Gulcher, Ferhat Meziani, Christiane Moog, Thomas W. Chittenden, Seiamak Bahram
Summary: In this study, multi-omics analysis and artificial intelligence were used to examine the differences in biological factors between critical and non-critical COVID-19 patients in a young and otherwise healthy cohort. The study identified ADAM9 as a driver of disease severity and a potential therapeutic target.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Immunology
Marc Scherlinger, Luc Pijnenburg, Emmanuel Chatelus, Laurent Arnaud, Jacques-Eric Gottenberg, Jean Sibilia, Renaud Felten
Summary: This study suggests that SARS-CoV-2 vaccination is well tolerated and immunogenic in the majority of patients with long-COVID or post-acute sequelae of COVID-19 (PASC). Disseminating these reassuring data might prove crucial to increasing vaccine coverage in patients with PASC.
Editorial Material
Rheumatology
Renaud Felten, Floriane Gallais, Cedric Schleiss, Emmanuel Chatelus, Rose-Marie Javier, Luc Pijnenburg, Christelle Sordet, Jean Sibilia, Laurent Arnaud, Samira Fafi-Kremer, Jacques-Eric Gottenberg
LANCET RHEUMATOLOGY
(2022)
Editorial Material
Rheumatology
Jean-Marie Berthelot, Frederic Liote, Jean Sibilia
Article
Rheumatology
Arthur Petitdemange, Renaud Felten, Jean Sibilia, Thierry Martin, Laurent Arnaud
Summary: The study reveals significant heterogeneity in antimalarial agent prescription among physicians treating lupus, with key unmet needs identified regarding this treatment approach. This highlights the importance of developing more comprehensive recommendations and promoting dissemination among healthcare providers.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2021)
Article
Rheumatology
A. Mariotte, L. Bernardi, C. Macquin, A. DeCauwer, I Kotova, S. Blueml, D. Noel, A. Scanu, L. Punzi, R. Carapitou, J. Sibilia, S. Bahram, P. Georgel
Summary: The study found marked overproduction of sMICA in the synovial fluid of patients with rheumatoid arthritis. Mouse studies demonstrated the complex transcriptional regulation of Nkg2d ligands encoding genes depending on the inflammatory setting and microenvironment. Quantification of sMICA could be an interesting biomarker for identifying acute inflammation in rheumatoid arthritis patients where classical markers are undetectable.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Laurent Arnaud, Philippe Mertz, Zahir Amoura, Reinhard E. Voll, Andreas Schwarting, Francois Maurier, Gilles Blaison, Bernard Bonnotte, Vincent Poindron, Christoph Fiehn, Hanns-Martin Lorenz, Anne-Sophie Korganow, Jean Sibilia, Thierry Martin
Summary: This study utilized latent class analysis to identify three distinct patterns of fatigue in a large international cohort of SLE patients, highlighting the importance of distinguishing between patients with active disease and those with high levels of fatigue, depression, and anxiety for appropriate treatment prioritization.
Article
Rheumatology
Renaud Felten, Marc Scherlinger, Aurelien Guffroy, Vincent Poindron, Alain Meyer, Margherita Giannini, Anne-Sophie Korganow, Christelle Sordet, Emmanuel Chatelus, Rose-Marie Javier, Aurore Meyer, Luc Pijnenburg, Jean-Francois Kleinmann, Jacques-Eric Gottenberg, Jean Sibilia, Thierry Martin, Laurent Arnaud
Summary: This study aimed to assess the prevalence of COVID-19 infection in patients with rare autoimmune diseases, and found a low prevalence of proven SARS-CoV-2 infection and very rare severe infections among these patients, which may be attributed to good compliance with prophylactic measures.
ARTHRITIS RESEARCH & THERAPY
(2021)
